AquaBounty Facing Environmental Complaint in Panama
By admin,
The Guardian
| 11. 23. 2013
A U.S. company with a Prince Edward Island research facility is facing a complaint in Panama alleging that it is in breach of the country’s environmental regulations.
The Environmental Advocacy Center of Panama submitted a complaint to the country’s National Environmental Authority earlier this week alleging that AquaBounty’s research and development of Genetically Modified (GM) Atlantic salmon is in breach of environmental regulations.
The company produces salmon eggs in P.E.I., which are then shipped to Panama for further research and development.
Sharon Labchuk, of the P.E.I. group “Islanders Say No to Frankenfish”, said she was surprised at the complaint.
“We always assume that because something is as controversial as this is, the proper controls are in place,” said Labchuk. “It’s also very experimental and the risks of anything going wrong are disastrous. They can wipe out the wild salmon population if these fish ever escape and their eggs end up in the wild rivers.”
The National Environmental Authority in Panama conducted an inspection of the AquaBounty operation in 2012 and allegedly found violations that remained uncorrected by the company. Those...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...